Pfizer Sues Novo Nordisk, Alleging $9B Metsera Bid Is A Stall Strategy
Benzinga
2025-11-04
Views 7
Pfizer sued Novo Nordisk, accusing it of using a $9 billion rival bid for Metsera to delay Pfizer’s $7.3 billion acquisition and stifle obesity-drug competition. Novo defended its offer as superior and compliant, while Metsera urged a judge to reject Pfizer’s attempt to block the deal.
Report form
RELATED VIDEOS
